EGFR ctDNA kvantativ vurdering for lungekræftscreening i asiatiske og latinske befolkninger (EQUAL)
EQUAL: EGFR ctDNA kvantativ vurdering for lungekræftscreening i asiatiske og latinske befolkninger
This research study is studying a new blood test to screen for Epidermal Growth Factor Receptor (EGFR) positive lung cancer in healthy individuals at risk for the disease and who cannot undergo regular lung cancer screening.
The name of the test used in this research study is:
-Circulating free DNA (cfDNA) Assay
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
The goal of this research study is to evaluate the feasibility of a novel EGFR blood plasma ctDNA screening test among East Asian and Latinx participants at risk for lung cancer and ineligible for regular lung cancer screening. The test looks for a gene change called Epidermal Growth Factor Receptor (EGFR), specifically EGFR L858R and exon 19 deletions, which comprise 85-90% of total EGFR mutations. This study seeks to determine if it is possible to use the blood test to detect this type of lung cancer that might not yet show symptoms.
The research study procedures include screening for eligibility, in-clinic visits, blood tests, and an optional questionnaire and/or focus group.
It is expected that about 1000 people will participate in the blood sample collection, 100 individuals in the survey, and 20 individuals in the focus groups.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Fernando Pacheco
- Telefonnummer: 857-215-2794
- E-mail: fernando_pacheco@dfci.harvard.edu
Undersøgelse Kontakt Backup
- Navn: Kylee Coonradt
- Telefonnummer: 617-582-8846
- E-mail: kylee_coonradt@dfci.harvard.edu
Studiesteder
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02215
- Rekruttering
- Dana-Farber Cancer Institute
-
Kontakt:
- Narjust Florez, MD
- Telefonnummer: 617-582-7335
- E-mail: narjust_florez@dfci.harvard.edu
-
Ledende efterforsker:
- Narjust Florez, MD
-
Boston, Massachusetts, Forenede Stater, 02215
- Ikke rekrutterer endnu
- Beth Israel Deaconess Medical Center
-
Kontakt:
- Daniel Costa, MD, PhD
- Telefonnummer: 617-667-7000
- E-mail: dbcosta@bidmc.harvard.edu
-
Ledende efterforsker:
- Daniel Costa, MD, PhD
-
Boston, Massachusetts, Forenede Stater, 02215
- Ikke rekrutterer endnu
- Massachusetts General Hospital
-
Kontakt:
- Lecia Sequist, MD, MPH
- Telefonnummer: 617-726-5130
- E-mail: lvsequist@mgb.org
-
Ledende efterforsker:
- Lecia Sequist, MD, MPH
-
Brighton, Massachusetts, Forenede Stater, 02135
- Ikke rekrutterer endnu
- Dana-Farber Cancer Institute at Steward St. Elizabeth's
-
Kontakt:
- Alys Malcolm, MD
- Telefonnummer: 617-632-4595
- E-mail: alys_malcolm@dfci.harvard.edu
-
Ledende efterforsker:
- Alys Malcolm, MD
-
Methuen, Massachusetts, Forenede Stater, 01844
- Ikke rekrutterer endnu
- Dana-Farber Cancer Instiute Merrimack Valley
-
Ledende efterforsker:
- Pedro Sanz-Altamira, MD
-
Kontakt:
- Pedro Sanz-Altamira, MD
- Telefonnummer: 978-620-2020
- E-mail: pedro_sanz-altamira@dfci.harvard.edu
-
South Weymouth, Massachusetts, Forenede Stater, 02190
- Ikke rekrutterer endnu
- Dana-Farber Cancer Institute South Shore
-
Kontakt:
- Shail Maingi, MD
- Telefonnummer: 781-624-5000
- E-mail: shail_maingi@dfci.harvard.edu
-
Ledende efterforsker:
- Shail Maingi, MD
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria (Aims 1, 2, and 3)
Group 1 - Healthy Individuals (50-80 years of age):
Non-tobacco using (currently). Self-identify as East Asian (including Southeast Asian) or Latinx/Hispanic. East Asian includes those who self-identify as Chinese, Japanese, Korean, Taiwanese, or Malaysian.
Southeast Asian includes those who self-identify as Cambodian, Thai, Vietnamese, or Filipino.
Latinx/Hispanic includes those who self-identify as a person of Central or South American or Caribbean culture or origin.
Countries of origin include:
East Asian: China, Japan, Korea, Mongolia, Singapore, Taiwan.
Southeast Asian: Brunei, Cambodia, Philippines, Laos, Malaysia, Myanmar, Thailand, Timor-Leste, Vietnam.
Latinx/Hispanic: Argentina, Belize, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominican Republic, Ecuador, El Salvador, Guatemala, Guyana, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Puerto Rico, Spain, Suriname, Trinidad and Tobago, Uruguay, Venezuela.
Group 2 - At-Risk Individuals (40-80 years of age):
Non-tobacco using (currently).
Individuals of any race or ethnicity who meet at least one of the following criteria:
Family history of any EGFR-mutant lung cancer. Personal history of chest radiation. History of tuberculosis (TB) infection, asthma requiring daily inhaled corticosteroids, or chronic bronchitis.
Symptoms of lung cancer for the past month, including unexplained weight loss, voice hoarseness, cough or worsening cough, or dyspnea or worsening dyspnea.
Excluding individuals who concurrently present with a viral infection, runny nose, sore throat, or productive cough with green or yellow sputum.
Additional Inclusion Criteria for Groups 1 and 2:
Aims 1 and 2: Able to complete and understand the study's informed consent in their preferred language.
Aim 3: Able to complete and understand the study's informed consent and participate in a focus group in English, Mandarin, Vietnamese, or Spanish.
Exclusion Criteria (Aims 1, 2, and 3) for Groups 1 and 2:
Having had a chest CT scan in the last 12 months or having an anticipated chest CT scan during the enrollment period.
Having a current cancer or history of cancer within the last 3 years, excluding localized skin cancer, breast ductal carcinoma in situ, and localized prostate cancer.
Hemoptysis. More than 400 lifetime cigarettes (i.e., 20 packs) of smoking or tobacco use. Adults unable to provide informed consent. Individuals younger than 40 years of age. Prisoners. Pregnant women. Personal diagnosis of lung cancer or testing for clinical suspicion of lung cancer.
Not able to comply with study requirements.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Screening
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: ctDNA Assay
All participants will be asked to provide blood samples and are administered a baseline questionnaire. The blood sample will be tested using the investigational ctDNA assay. If the investigational test is positive, these participants will be followed up by CLIA verification of results. A positive CLIA result will be followed up by a lung CT scan. A positive CT scan will be followed up by referral for further evaluation. A negative CT scan will be followed up by a repeat scan in 12 months. Participants will be notified of results. Additionally, participants may participant in optional studies: 1) One-time survey regarding perception of lung cancer screening and ctDNA testing, 2) Virtual focus group, 3) Blood banking study |
Screening investigational blood test to test for EGFR L858R and exon 19 deletions, which comprise 85-90% of total EGFR mutations. A positive or indeterminate investigational test will be followed up by CLIA verification of results. A positive or indeterminate CLIA result will be followed up by a lung CT scan. A positive CT scan will be followed up by referral for further evaluation. A negative CT scan will be followed up by a repeat scan in 12 months. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Detection Rate of Non-Small Cell Lung Cancer
Tidsramme: 2 years
|
The proportion of participants with a positive assay result who are subsequently diagnosed with lung cancer through clinical pathology, among all participants tested with the assay. |
2 years
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Testing Turnaround Time
Tidsramme: Up to 2 years
|
The duration from the time of blood draw to the release of the ctDNA testing results to the study team. |
Up to 2 years
|
|
Recruitment Acceptability
Tidsramme: Up to 2 years
|
Determining proportion of screened patients who are eligible and who consent to the trial at each collaboration site |
Up to 2 years
|
|
Barriers to Sample Acquisition
Tidsramme: Up to 2 years
|
Examining barriers impeding scale-up of sample collection, handling, and delivery |
Up to 2 years
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Ledende efterforsker: Narjust Florez, MD, Dana-Farber Cancer Institute
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 24-415
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
IPD-delingstidsramme
Data can be shared no earlier than 1 year following the date of publication
IPD-delingsadgangskriterier
Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .